rVWF: treatment finally reaches the modern age.
In this issue of Blood, Gill et al describe the results of the first phase 3 clinical trial evaluating recombinant von Willebrand factor (rVWF) for the treatment of hemorrhagic events in all patients with von Willebrand disease (VWD).
DUKE UNIVERSITY.
Ara D
AD
Metjian
D005260:Female; D006490:Hemostatics; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000493:pharmacokinetics*; D014842:von Willebrand Diseases / Q000188:drug therapy*; D014841:von Willebrand Factor / Q000493:pharmacokinetics*
D006490:Hemostatics; D011994:Recombinant Proteins; D014841:von Willebrand Factor